Test Price
2,800 AED✅ Home Collection Available
APOA1 Gene Hypoalphalipoproteinemia Genetic Test in UAE | 2800 AED | DHA-Licensed Molecular Lab
Executive Summary & Core Metrics
Test Overview & Methodology
The APOA1 gene encodes apolipoprotein A-I, the major protein component of HDL (good cholesterol). Pathogenic variants cause primary hypoalphalipoproteinemia—an inherited metabolic disorder marked by extremely low HDL and accelerated atherosclerosis. This NGS test screens the entire coding region and splice sites to guide precise cardiovascular risk management.
| Feature | Our APOA1 NGS Test | Standard Lipid Panel + Limited Genotyping |
|---|---|---|
| Precision | Full gene – detects all pathogenic SNVs, indels, CNVs | Only common variants or biochemical phenotype |
| Method | Next Generation Sequencing (Illumina® platform) | Enzymatic colorimetric / targeted SNP array |
| Clinical Utility | Root cause diagnosis, family screening, personalised therapy | Risk estimation; cannot confirm monogenic aetiology |
| Turnaround | 3 – 4 Weeks | 2 – 7 days (for lipid panel) |
Physician Insight & Safety Protocols
“This APOA1 gene test provides a definitive molecular diagnosis for primary hypoalphalipoproteinemia, but a low HDL can also arise from metabolic syndrome, certain medications, or chronic inflammatory states. I carefully correlate genetic results with a complete lipid profile, cardiac imaging, and family history to avoid misclassification. Any therapeutic changes based on this result must be integrated into the broader clinical picture by the treating specialist.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Advisory Notice: Medication & Safety
Important Medication & Safety Notice
Do not discontinue prescribed medication without consulting your doctor.
Statins, fibrates, or other lipid regulators should never be stopped based solely on a pending genetic report. Always discuss any changes with your treating cardiologist or primary physician.
Exclusion Criteria & Emergency Red Flags
- Minors under 18 years without compliant consent (parental/legal guardian) in line with Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Elective genetic testing during pregnancy unless explicitly advised by a maternal-fetal medicine specialist.
- Active febrile illness or severe anaemia (Hb <7 g/dL) that may affect sample integrity.
- Known bleeding diathesis or current anticoagulant therapy that precludes safe venipuncture—discuss alternative sample (FTA card or extracted DNA).
🚨 Seek Emergency Care Immediately If You Experience:
- Acute crushing chest pain, dyspnoea, or palpitations.
- Sudden vision loss, slurred speech, or unilateral weakness.
- Signs of acute pancreatitis (severe epigastric pain radiating to the back).
Patient FAQ & Clinical Guidance
1. What is the APOA1 Gene Hypoalphalipoproteinemia Genetic Test?
This test sequences the entire APOA1 gene to identify pathogenic variants that cause primary hypoalphalipoproteinemia. It examines all coding regions and splice sites for SNVs, indels, and CNVs. A positive result confirms the genetic basis of extremely low HDL, enabling targeted therapy and family cascade screening.
2. How should I prepare, and what sample types are accepted?
You can provide a whole blood sample, extracted DNA, or a single drop of blood on an FTA card—no fasting required. A genetic counselling session is recommended beforehand to draw a detailed pedigree and ensure appropriate test selection. Our DHA-licensed mobile phlebotomist will collect the sample at your home or office between 8 AM and 11 PM.
3. Who should consider this test and how are the results acted upon?
Individuals with persistent low HDL (<30 mg/dL), premature coronary artery disease, or a strong family history of hypoalphalipoproteinemia benefit most from this. A positive result guides early statin/fibrate use, lifestyle interventions, and screening of first-degree relatives. Negative results may shift focus to acquired causes; however, clinical correlation with a cardiologist or lipid specialist remains essential.
UAE Regulatory & Data Privacy Adherence
Data Protection: This test complies with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data is encrypted and accessible only by authorized personnel.
Clinical Safety: Patient consent and medical liability are governed by Federal Decree-Law No. 4 of 2016 on Medical Liability.
Laboratory Accreditation: DHA Facility License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | Corporate Lab: DNA Labs UAE.
Clinical & Logistical Metadata
| Test Name | APOA1 Gene Hypoalphalipoproteinemia Genetic Test (NGS) |
| Price (AED) | 2,800 |
| Turnaround Time | 3 – 4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood (EDTA), Extracted DNA, or FTA Dried Blood Spot |
| Methodology Used | Next Generation Sequencing (NGS) – Illumina® Platform |
| ICD-10-CM Code | E78.6 (Lipoprotein deficiency) |
| LOINC Code | 93977-2 (APOA1 gene mutation analysis) |
| DHA Facility License & Lab Address | 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | Corporate Lab: DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians